Eli Lilly has requested Europe's drug regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said ...

Shares in pharmaceuticals giant Eli Lilly (LLY) were looking perkier today after it ramped up its battle to get a key ...

The second U.S. drug shown to slow the progression of early Alzheimer's has arrived in Seattle-area clinics. One of the first ...

Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

Susan Aaron was an active 74-year-old retiree with Alzheimer’s who was told she might experience extreme fatigue and terrible headaches if she tried a new drug from Eisai Co. that promised to slow the ...

pointing out that the drug has already been approved in the US, China, Japan, and other world markets for people with the early signs of Alzheimer's. "Lilly remains confident in the safety and ...

Consider Verzenio, a cancer drug ... Eli Lilly's greatest strength is proving to be its innovative abilities. Whether it's in diabetes, weight loss, Alzheimer's disease, immunology, or oncology ...

Lilly said the US regulator “wants to further ... Howard Fillit, co-founder and chief science officer of the Alzheimer’s Drug Discovery Foundation (ADDF), put the delay into perspective ...

Lilly said Friday that it hopes discussions about the drug continue with the agency ... that target one contributor to Alzheimer’s — sticky amyloid plaque buildup in the brain.